The Antiemetic Activity of High-Dose Metoclopramide and High-Dose Alizapride in Combination with Lorazepam in Patients Receiving Cancer Chemotherapy
作者:
Annamaria Molina,
Luigi Guglielmo,
Maria Eugenia Azzolini,
Pasqualina Biondani,
Maria Carla Capelli,
Antonio Grandinetti,
Claudia Griso,
Giovanni Martinelli,
Nello Martini,
Roberta Zanotti,
Gian Luigi Cetto,
期刊:
Oncology
(Karger Available online 1991)
卷期:
Volume 48,
issue 2
页码: 111-115
ISSN:0030-2414
年代: 1991
DOI:10.1159/000226907
出版商: S. Karger AG
关键词: Antiemesis during chemotherapy;Metoclopramide-alizapride;Antiemesis during platinum therapy
数据来源: Karger
摘要:
The antiemetic efficacy of metoclopramide and lorazepam (MTC + L) versus alizapride and lorazepam (ALZ + L) was compared in 100 patients receiving chemotherapy, in a prospective randomized double-blind study. In highly emetogenic (HE) regimen (including platinum) patients received MTC 1 mg/kg or ALZ 3 mg/kg × 4 doses, and lorazepam 2.5 mg 30 min before therapy. In moderately emetogenic (ME) regimen patients received MTC 0.5 mg/kg or ALZ 1.5 mg/kg x 3 doses, and lorazepam 2.5 mg 30 min before therapy. In both HE and ME regimen groups there was no statistically significant difference between MTC + L and ALZ + L treatments as regards the number of vomiting episodes, the duration of emesis and nausea, the intensity of nausea and side effects, but a statistically significant difference between treatments was found in the HE group where MTC-L was superior to ALZ + L in obtaining complete protection from vomiting (37 vs 11%, p = 0.05). No significant difference in side effects was observed
点击下载:
PDF
(2003KB)
返 回